Canada: NAFTA Tribunal Finds Promise Doctrine Founded In 35 Plus Years Of Canadian Jurisprudence – Not A Dramatic Change In The Requirements For Patent Utility


Eli Lilly's arguably last ditch attempt to challenge the Canadian courts' invalidation of two Canadian patents relating to the drugs olanzapine (Zyprexa") and atomoxetine (Strattera"), using a NAFTA arbitration, has been rejected.1 Eli Lilly's case was based on demonstrating a "dramatic change in Canadian patent law" relating to the introduction of the Promise doctrine into the utility requirement. In its March 16, 2017 decision (the "Decision"), the Tribunal found that Eli Lilly had failed to establish a factual basis for its characterization of Canadian common law violating NAFTA2:

"the alleged promise utility doctrine had a foundation in Canadian law when Claimant's patents were filed. At that time, although Claimant may not have been able to predict the precise trajectory of the law on utility, it should have, and could have, anticipated that the law would change over time as a function of judicial decision-making. The record in this case shows that the law did in fact undergo a reasonable measure of change and development."3


Although the Decision provides a useful historical analysis of Canadian jurisprudence regarding the Promise doctrine from as early as 1979 (Monsanto)4 and 1981 (Consolboard)5, as discussed in the 2002 AZT decision (Apotex Inc. v. Wellcome Foundation Ltd., 2002 SCC 77) of the Supreme Court of Canada ("SCC"), up to the present, the Tribunal was careful to repeatedly note that its role was not to question the legal analysis of Canadian courts, or Canada's policy choices6. "[A] NAFTA Chapter Eleven tribunal is not an appellate tier with a mandate to review the decisions of the national judiciary."7 The Decision focused instead on whether there was a dramatic change in patent law over 2002-2008 as argued by Eli Lilly.

Eli Lilly's "dramatic change" argument, "outside the 'acceptable margin of change' that investors must anticipate" was based on Canada's alleged "adoption of a completely new doctrine in a well-settled area"8. The three main areas of the Promise doctrine that Eli Lilly alleged had dramatically changed were as follows:

  1. setting the Promise (the alleged change was that courts are now scouring the disclosure, not even the claims, to find an elevated Promise, instead of requiring only the traditional mere scintilla of utility)9;
  2. the use of post-filing evidence (the alleged change was that courts now do not permit a patentee to rely on tests post filing to support actual utility); and
  3. the disclosure required in a patent for a sound prediction (the alleged change was that there is now a heightened disclosure requirement to include the facts and line of reasoning a patentee relies on for its prediction, although there was acknowledgement that this requirement is currently unclear in recent jurisprudence).

Notably, these three areas had negative consequences for Eli Lilly's two patents. The olanzapine patent was a selection patent which was held by the Canadian courts not to have met the promise, at the time of filing, that olanzapine "would provide markedly superior clinical treatment of schizophrenia with a better side-effects profile than other known antipsychotics," when administered over a long term.10 The atomoxetine patent was a new use patent which was held by the Canadian courts not to have met the promise, at the time of filing, that atomoxetine was clinically useful for treating ADHD.11 As would be expected, in restricting its analysis to the ultimate threshold question as to whether there was a "dramatic change" in Canadian patent law, the Decision contains only cursory references to Eli Lilly's two patents. Instead, the Tribunal concentrated on the fact that the Canadian decisions invalidating these patents for inutility12, and the three main areas of the Promise doctrine, were based on, and rooted in, Canadian jurisprudence over the past 35 plus years. Procedures at the Canadian Patent Office were also reviewed, including the fact that Eli Lilly was made aware of utility requirements during prosecution of its two patents, when it received "Office Actions that called for disclosure of the basis for a sound prediction."13

In its analysis, the Tribunal found:

  • there was no factual basis for an expropriation of Eli Lilly's investment (its two patents) under NAFTA section 1110 by Canada's actions (through Canadian common law)14;
  • there was no factual basis for a violation of minimum standards of treatment regarding fair and equitable treatment under NAFTA section 1105(1)15; and
  • the Promise doctrine is rationally connected to the legitimate policy of discouraging overstatements in patent disclosures, especially in the context of "new use" and "selection" patents16 – notably, the Tribunal did not need to consider whether this was the only, or best means of, achieving this objective.

It will be interesting to see whether the SCC comments on the Decision in its eagerly-anticipated judgment regarding the Promise of AstraZeneca's esomeprazole patent17, which should provide much-needed guidance with respect to setting the Promise. Before the SCC, AstraZeneca had characterized Canada's Promise doctrine as "a utility requirement ...that is out of step with the corresponding requirements in other major jurisdictions," resulting in Eli Lilly's NAFTA challenge. Notably, the Decision, in fact, states that any alleged major differences with other jurisdictions are irrelevant to the central question as to whether there was a dramatic change in Canadian patent law. In any event, the single 2014 U.S. Trade Report, as relied on by Eli Lilly outlining "serious concerns about ... heightened utility requirements" in Canada, was characterized by the Tribunal as an outlier: "silence [from any other State] speaks louder than the single, brief criticism."


1. Final Award, Case No. UNCT/14/2, dated March 16, 2017 (Tribunal of the International Centre for Settlement of Investment Disputes);

2. The Decision, para. 307

3. Para. 384

4. Paras. 341, 342, referring to the SCC's decision in Monsanto Co. v. Canada (Commissioner of Patents), [1979] 2 SCR

5. Para. 316, 317, referring to the SCC's decision in Consolboard Inc. v. MacMillan Bloedel (Sask) Ltd., [1981] 1 S.C.R. 504

6. Paras. 224, 327, 331, 426, 430

7. Para. 225

8. Para. 269

9. The argument that there is no Promise doctrine, and only de minimus utility, in respect of a compound only claim (as opposed to a use claim), irrespective of what the disclosure says, is currently the crux of the issue pending before the SCC in Astra's esomeprazole case.

10. Eli Lilly Canada Inc. v. Novopharm Ltd., 2011 FC 1288, ¶ 273, aff'd Eli Lilly Canada Inc. v. Novopharm Ltd., 2012 FCA 232.

11. Novopharm Ltd. v. Eli Lilly & Co., 2010 FC 915, aff'd Eli Lilly & Co. v. Teva Canada Ltd., 2011 FCA 220.

12. Para. 430

13. Paras. 289, 345, 346

14. Paras. 226, 469

15. Paras. 226, 469

16. Para. 423

17. AstraZeneca Canada v. Apotex (Esomeprazole), SCC Court File No. 36654

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.